{"id":891,"date":"2012-07-25T20:18:25","date_gmt":"2012-07-25T20:18:25","guid":{"rendered":"http:\/\/ctcps.org\/blog\/?p=891"},"modified":"2013-01-22T18:05:40","modified_gmt":"2013-01-22T18:05:40","slug":"drug-companies-drive-the-psychiatric-drugging-of-children","status":"publish","type":"post","link":"https:\/\/blog.ctcps.org\/?p=891","title":{"rendered":"Drug Companies Drive the Psychiatric Drugging of Children"},"content":{"rendered":"<p>Posted: 07\/24\/2012 11:24 am Huffington Post\u00a0 |\u00a0 Dr. Peter Breggin, reform psychiatrist with Ginger Breggin &#8211; Johnson &amp; Johnson, the company that makes the antipsychotic drug Risperdal, has tentatively agreed to a settlement of $2.2 billion to resolve a federal investigation into the company&#8217;s marketing practices. Although details are not fully finalized, this includes &#8220;a roughly $400 million criminal fine for the illegal promotion of the antipsychotic Risperdal,&#8221; according to the Wall Street Journal. It&#8217;s been well documented that Johnson &amp; Johnson confidentially paid psychiatrists such as Harvard&#8217;s Joseph Biederman to promote adult drugs such as the powerful antipsychotic drug Risperdal for children. The company has even ghost-written at least one of the Harvard professor&#8217;s &#8220;scientific&#8221; articles.\u00a0 <a href=\"http:\/\/www.huffingtonpost.com\/dr-peter-breggin\/psychiatric-drugs_b_1693649.html\">Read more<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Posted: 07\/24\/2012 11:24 am Huffington Post\u00a0 |\u00a0 Dr. Peter Breggin, reform psychiatrist with Ginger Breggin &#8211; Johnson &amp; Johnson, the company that makes the antipsychotic drug Risperdal, has tentatively agreed <\/p>\n<p class=\"readMore\"><a class=\"read-more\" href=\"https:\/\/blog.ctcps.org\/?p=891\">Read More<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[6],"tags":[356,343,236,372,373,172,374],"class_list":["post-891","post","type-post","status-publish","format-standard","hentry","category-newsroom","tag-eli-lilly","tag-glaxosmithkline","tag-johnson-johnson","tag-justice-department","tag-mental-illness","tag-pfizer","tag-pharmaceutical-industry"],"_links":{"self":[{"href":"https:\/\/blog.ctcps.org\/index.php?rest_route=\/wp\/v2\/posts\/891","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blog.ctcps.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blog.ctcps.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blog.ctcps.org\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/blog.ctcps.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=891"}],"version-history":[{"count":4,"href":"https:\/\/blog.ctcps.org\/index.php?rest_route=\/wp\/v2\/posts\/891\/revisions"}],"predecessor-version":[{"id":1151,"href":"https:\/\/blog.ctcps.org\/index.php?rest_route=\/wp\/v2\/posts\/891\/revisions\/1151"}],"wp:attachment":[{"href":"https:\/\/blog.ctcps.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=891"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blog.ctcps.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=891"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blog.ctcps.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=891"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}